Xantos to Use Atugen s RNAi Compounds for Cancer Target Validation

Apr 15, 2005

NEW YORK, April 15 (GenomeWeb News) - Xantos Biomedicine today announced an agreement to use Atugen's atuRNAi short interfering RNAi compounds to validate an angiogenic target in animal studies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Prize for Five

Five researchers are to share this year's Albany Medical Center Prize for their work on the CRISPR/Cas9 gene-editing tool, the AP reports.

Sure, Blame the Test

Stat News reports on how white supremacists cope with surprising genetic ancestry testing results.

This Week in Genome Research

In Genome Research this week: sex-biased gene expression evolution in malaria mosquitos, method to find ancient selective sweeps, and more.

Low Down Syndrome Rates in Iceland

Iceland has nearly eliminated Down syndrome from its population, CBS News reports.

Main menu